Macquarie Group’s Ovid Therapeutics OVID Stock Holding History

Macquarie Group’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,113	Closed	-$30K	–	2388
2020 Q1	$30K	Buy	+10,113	New	+$34.1K	﹤0.01%	1886

Other funds holding OVID

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's OVID Position: Q2 2020 in Review

Macquarie Group sold out of Ovid Therapeutics (OVID) in Q2 2020, closing a stake of 10,113 shares — an estimated $30K sold.

Macquarie Group first reported a position in OVID in Q1 2020 and held it in 1 quarter. The position peaked at $30K in Q1 2020. 79 funds tracked by Wall St. Rank hold OVID as of Q2 2020.

Macquarie Group reported no remaining Ovid Therapeutics position as of Q2 2020 after selling out during the quarter.
Macquarie Group sold 10,113 Ovid Therapeutics shares in Q2 2020, an estimated $30K.
Macquarie Group first reported a position in Ovid Therapeutics in Q1 2020 and held it in 1 quarter.
Macquarie Group's Ovid Therapeutics position peaked at $30K in Q1 2020.
79 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2020.

Based on Macquarie Group's 13F filing for Q2 2020, filed 11 Aug 2020.